[HTML][HTML] Targeting KRAS in Cancer: Promising Therapeutic Strategies
LM Mustachio, A Chelariu-Raicu, L Szekvolgyi… - Cancers, 2021 - mdpi.com
Simple Summary Since the Kirsten rat sarcoma viral oncogene homolog (KRAS) is mutated
in about 25% of all human cancers and is at the center of pathways involved in …
in about 25% of all human cancers and is at the center of pathways involved in …
Targeting KRAS in Cancer: Promising Therapeutic Strategies
LM Mustachio, A Chelariu-Raicu, L Szekvolgyi… - …, 2021 - pubmed.ncbi.nlm.nih.gov
The Kirsten rat sarcoma viral oncogene homolog (KRAS) is mutated in approximately 25%
of all human cancers and is known to be a major player promoting and maintaining …
of all human cancers and is known to be a major player promoting and maintaining …
[HTML][HTML] Targeting KRAS in Cancer: Promising Therapeutic Strategies
LM Mustachio, A Chelariu-Raicu, L Szekvolgyi… - Cancers, 2021 - ncbi.nlm.nih.gov
The Kirsten rat sarcoma viral oncogene homolog (KRAS) is mutated in approximately 25%
of all human cancers and is known to be a major player promoting and maintaining …
of all human cancers and is known to be a major player promoting and maintaining …
Targeting KRAS in Cancer: Promising Therapeutic Strategies.
LM Mustachio, A Chelariu-Raicu, L Szekvolgyi… - …, 2021 - search.ebscohost.com
Abstract Simple Summary: Since the Kirsten rat sarcoma viral oncogene homolog (KRAS) is
mutated in about 25% of all human cancers and is at the center of pathways involved in …
mutated in about 25% of all human cancers and is at the center of pathways involved in …
[PDF][PDF] Targeting KRAS in Cancer: promising Therapeutic Strategies
LM Mustachio, A Chelariu-Raicu, L Székvölgyi… - dea.lib.unideb.hu
The Kirsten rat sarcoma viral oncogene homolog (KRAS) is mutated in approximately 25%
of all human cancers and is known to be a major player promoting and maintaining …
of all human cancers and is known to be a major player promoting and maintaining …
Targeting KRAS in Cancer: Promising Therapeutic Strategies
LM Mustachio, A Chelariu-Raicu, L Szekvolgyi… - …, 2021 - epub.ub.uni-muenchen.de
Since the Kirsten rat sarcoma viral oncogene homolog (KRAS) is mutated in about 25% of
all human cancers and is at the center of pathways involved in tumorigenesis, it is necessary …
all human cancers and is at the center of pathways involved in tumorigenesis, it is necessary …
Targeting KRAS in cancer: Promising therapeutic strategies
LM Mustachio, A Chelariu-Raicu… - …, 2021 - mdanderson.elsevierpure.com
The Kirsten rat sarcoma viral oncogene homolog (KRAS) is mutated in approximately 25%
of all human cancers and is known to be a major player promoting and maintaining …
of all human cancers and is known to be a major player promoting and maintaining …
Targeting KRAS in Cancer: Promising Therapeutic Strategies
LM Mustachio, A Chelariu-Raicu, L Szekvolgyi… - CANCERS, 2021 - real.mtak.hu
The Kirsten rat sarcoma viral oncogene homolog (KRAS) is mutated in approximately 25%
of all human cancers and is known to be a major player promoting and maintaining …
of all human cancers and is known to be a major player promoting and maintaining …
Targeting KRAS in Cancer: Promising Therapeutic Strategies.
LM Mustachio, A Chelariu-Raicu, L Szekvolgyi… - Cancers, 2021 - europepmc.org
The Kirsten rat sarcoma viral oncogene homolog (KRAS) is mutated in approximately 25%
of all human cancers and is known to be a major player promoting and maintaining …
of all human cancers and is known to be a major player promoting and maintaining …
Targeting KRAS in Cancer: Promising Therapeutic Strategies
LM Mustachio, A Chelariu-Raicu, L Szekvolgyi… - Cancers, 2021 - cir.nii.ac.jp
抄録< jats: p> The Kirsten rat sarcoma viral oncogene homolog (KRAS) is mutated in
approximately 25% of all human cancers and is known to be a major player promoting and …
approximately 25% of all human cancers and is known to be a major player promoting and …